Clinical Trial Update: Merestinib In Non-Small Cell Lung Cancer And Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update for merestinib in non-small cell lung cancer and solid tumors; study terminated with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma
• Solid Tumor

Drugs mentioned

• Merestinib (merestinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Carcinoma, Non-Small-Cell Lung, Solid Tumor | Phase 2 | Status: TERMINATED | Results posted: 2024-04-11